Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...
Ocuphire Pharma has announced the acquisition of Opus Genetics to develop gene therapies for inherited retinal diseases (IRDs ...
Gov. Kathy Hochul announced plans to build a $430 million New York BioGenesis Park — a cell and gene therapy lab — in Lake ...
By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...
Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.
Researchers have used artificial intelligence to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types. Their new approach opens the ...
MyChesCo on MSN4h
Ocugen Advances Stargardt Disease Trial with Promising Gene Therapy(NASDAQ: OCGN) has announced a significant development in its efforts to treat Stargardt disease, as the Data and Safety Monitoring Board (DSMB) has greenlit the enrollment for the second phase of ...
Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise ...
The team has developed synthetic 'DNA switches' that can control genes in certain cells. It's believed the technology could ...
RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback